Cite
HARVARD Citation
Granger, K. et al. (2023). Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. Journal of oncology pharmacy practice. pp. 722-726. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Granger, K. et al. (2023). Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. Journal of oncology pharmacy practice. pp. 722-726. [Online].